(MCK) McKesson Corporation Company Overview

What does McKesson do?

McKesson Corporation is a New York Stock Exchange listed healthcare services company under ticker MCK. Its role is not mainly to invent drugs; it is to move, finance, support, and digitize parts of the healthcare supply chain so medicines, specialty therapies, medical products, and patient-access services reach pharmacies, hospitals, physician practices, biopharma companies, payers, and government customers. McKesson describes itself in its fiscal 2026 Form 10-K as a diversified healthcare services leader, with a fiscal year that ends on March 31.

What role does McKesson play in the healthcare chain?

The company sits between manufacturers, care sites, pharmacies, and patients. Its North American Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs in the United States and Canada. Its Oncology & Multispecialty platform supports community oncology, specialty drug distribution, practice management, clinical research, ophthalmology and retina management, and real-world evidence services. Its Prescription Technology Solutions business connects biopharma brands, providers, pharmacies, payers, and patients around access, affordability, and adherence. Medical-Surgical Solutions supplies non-acute care settings with medical products, laboratory equipment, logistics, and related services.

How does McKesson make money?

McKesson monetizes scale, logistics, service breadth, specialty capabilities, and technology-enabled access workflows. The main economic engine is high-volume pharmaceutical distribution, where revenue is very large but margin percentages are thin. The strategic growth layer is the set of higher-margin services around oncology, specialty practices, biopharma access, reimbursement, and prescription technology. That is why a simple revenue chart can mislead: the biggest revenue segment is not necessarily the best margin segment.

Where does revenue come from?

McKesson’s official business-segment description makes the revenue logic clear: North American Pharmaceutical is the largest segment, Oncology & Multispecialty is the specialty-care expansion platform, Prescription Technology Solutions is a healthcare connectivity and access business, and Medical-Surgical Solutions is a non-acute medical products and logistics business.

How does cash flow through the model?

The model starts with enormous product throughput, but the investor question is not only revenue growth. It is whether McKesson can preserve spread, collect receivables, manage inventory, fund acquisitions, comply with regulation, and still return cash. In FY2026, free cash flow was $5.4B after $745M of capital expenditures, showing that small reported margins can still create large absolute cash generation when the asset turns are high.

Which segments matter most to McKesson's economics?

The segment mix is the core of McKesson analysis. North American Pharmaceutical generated about 83.4% of FY2026 revenue, but only about 49.6% of reported segment operating profit before corporate expenses and interest. Prescription Technology Solutions generated only about 1.4% of FY2026 revenue, yet its 18.0% segment operating margin was far above the distribution segments. This explains why management emphasizes specialty, oncology, biopharma services, and technology access workflows.

Why does revenue not equal margin?

Drug distribution resembles a scale-and-throughput model: massive invoices, thin operating margins, and meaningful working-capital exposure. Specialty practice services and prescription technology can be smaller but more margin-relevant because they solve complex workflow problems, including patient access, reimbursement, data, and provider support. The company says Prescription Technology Solutions has connections with most electronic health record systems, over 50,000 pharmacies, more than 1,000,000 providers, most PBMs and health plans, and has supported over 650 biopharma brands.

What does the latest FY2026 reporting period show?

The newest full reporting package available is McKesson’s fourth-quarter and fiscal-year 2026 release for the period ended March 31, 2026. In the FY2026 fourth-quarter and full-year earnings release, the company reported Q4 revenue of $96.3B, up 6%, and FY2026 revenue of $403.4B, up 12%. Management attributed Q4 growth to oncology and multispecialty products, acquisition contributions, and North American prescription volume, partly offset by lower branded pharmaceutical contribution.

What changed in Q4 FY2026?

How should the latest annual numbers be read?

For the full fiscal year, McKesson generated $6.2B of operating cash flow, invested $745M in capital expenditures, produced $5.4B of free cash flow, and returned $5.1B to shareholders. The annual income statement also shows how thin distribution economics are: FY2026 gross profit was $14.6B on $403.4B of revenue, and operating income was $6.2B. The strength of the model is not high gross margin; it is the combination of scale, operational discipline, customer concentration management, and capital returns.

What strategic turning points still shape McKesson today?

McKesson is a case study in how a wholesaler can keep changing its relevance. The company began as a drug import and wholesale business, built national distribution scale, expanded into pharmacy and medical-surgical services, and has recently shifted toward more focused healthcare services and specialty platforms. The official company history connects the 1833 origin to public-health distribution roles, specialty oncology acquisitions,and emergency-response logistics.

Which historical decisions matter for today's model?

1. 1833
   John McKesson and Charles Olcott opened a drug import and wholesale business, creating the foundation for a logistics-centered healthcare model.
2. 1960s
   The company had built a national wholesale pharmaceutical distribution network, which still explains its scale advantage.
3. 1991-2006
   McKesson expanded pharmacy services, healthcare technology, and medical-surgical distribution, broadening beyond drug wholesaling.
4. 2006
   The CDC selected McKesson for the Vaccines for Children distribution program, illustrating its role in public-health logistics.
5. 2009
   McKesson partnered with the CDC as sole H1N1 vaccine distributor, deploying over 125M doses to as many as 90,000 U.S. sites.
6. 2020-2023
   During the COVID-19 pandemic, McKesson served as the U.S. government’s centralized distributor for vaccines, ancillary supply kits, and critical products.
7. 2026
   The company operated under a four-segment structure and advanced a Medical-Surgical Solutions separation, focusing the portfolio toward higher-margin healthcare services.

How did portfolio optimization change the story?

The most recent strategic move is not an acquisition alone; it is a portfolio refinement. McKesson completed the sale of its Norway retail and distribution businesses in January 2026, representing the final phase of its exit from European activities. In June 2026, McKesson closed an Apollo Funds investment in Medical-Surgical Solutions: Apollo invested $1.25B in convertible preferred equity for approximately 13% of MMS, valuing the business at about $13B, while McKesson retained operating control and majority ownership according to the official closing announcement.

Why do distribution scale and specialty oncology platforms protect McKesson?

McKesson’s moat is not a single patent or consumer brand. It is a system of scale, relationships, regulated execution, distribution infrastructure, data connectivity, and specialized provider services. In distribution, buyers care about reliability, product availability, compliance, and cost. In specialty oncology and prescription access, the value proposition extends into practice operations, clinical trial support, reimbursement, affordability, and real-world evidence. These capabilities make the company more than a commodity wholesaler.

Which competitors pressure the business?

The 10-K names Cencora, Inc. and Cardinal Health, Inc. as primary competitors in distribution, wholesaling, and logistics. It also notes competition from specialty distributors, GPOs, specialty pharmacies, oncology networks, ophthalmology and retina management providers, healthcare technology firms, clinical research organizations, and national or regional medical-supply distributors. This is not a winner-take-all platform market; it is a scale-and-service market where price, quality, assortment, innovation, emerging technologies, and convenience are competitive variables.

What makes the moat durable?

Three factors matter most. First, distribution scale lowers unit logistics costs and improves service breadth. Second, regulatory and compliance infrastructure creates entry barriers because pharmaceutical and controlled-substance distribution requires licenses, systems, monitoring, and audit readiness. Third, specialty platforms create switching costs for practices and biopharma partners because McKesson can combine drug access, GPO economics, technology, clinical research, and data insight inside the same ecosystem.

How do working capital, opioid liabilities, and buybacks shape financial strength?

McKesson’s financial health must be read differently from a software company or branded-drug manufacturer. Reported stockholders’ equity is a deficit because buybacks have been large; that does not automatically mean operating distress, but it does make conventional debt-to-equity ratios less useful. The better questions are whether McKesson generates enough cash, manages working capital, carries manageable debt, and can fund legal, regulatory, and portfolio commitments.

Which ratios best explain financial health?

What does capital allocation say?

McKesson’s FY2026 capital allocation was shareholder-return heavy. The company repurchased $4.8B of common stock, paid $381M of dividends, and declared $3.17 per share in regular cash dividends for FY2026. The board also approved an additional $5.0B authorization in April 2026, bringing total authorized repurchases to $7.7B as of April 2026. That pattern means per-share growth is partly an operating story and partly a capital-allocation story.

Who owns McKesson stock, and what does governance signal?

McKesson has a dispersed public ownership profile rather than a controlled founder structure. Each common share has one vote. The latest 2026 proxy statement reports 117,077,745 shares outstanding as of May 27, 2026. The two disclosed holders above 5% were BlackRock and Vanguard Capital Management LLC, and directors, named executive officers, and executive officers as a group held less than 1%.

Who has influence?

How do leadership and incentives matter?

Brian S. Tyler became Chair of the Board effective May 1, 2026, while the independent directors appointed Dominic J. Caruso as Lead Independent Director. The proxy also states that management and board representatives reached out to shareholders representing about 60% of outstanding common stock and engaged with holders representing about 46% on governance topics during the year. Compensation design is relevant because adjusted EPS is a central incentive-plan metric, which aligns with the company’s focus on operating performance and per-share value creation.

What opportunities and risks could change McKesson's outlook?

The opportunity side is clear: growth in specialty and oncology therapies, biopharma services, prescription access tools, distribution automation, AI-enabled efficiency, and portfolio simplification. Management’s FY2027 outlook called for adjusted EPS of $43.80 to $44.60 and reaffirmed a long-term adjusted EPS growth target of 13% to 16%. But the risk side is equally company-specific: customer concentration, healthcare regulation, controlled-substance litigation, cybersecurity, supply disruptions, and separation execution could all affect the model.

Which growth drivers deserve the most attention?

Which risks are most material?

Which KPIs should students and investors monitor?

The most useful watchlist is specific to the model: segment revenue growth, segment operating profit margin, cash flow from operations, free cash flow after capital expenditures, customer concentration, days sales outstanding, inventory days, drafts and accounts payable days, opioid-liability accruals, share count, and progress on Medical-Surgical separation. Those metrics reveal whether McKesson is improving the quality of earnings rather than merely increasing gross revenue.

Why does McKesson matter for valuation and research takeaway?

McKesson matters in valuation because it combines three profiles that normally require different models: a high-volume, low-margin distributor; a specialty healthcare services platform; and a capital-return compounder. A DCF model should not extrapolate revenue alone. It should connect revenue mix to gross profit, segment operating profit, working capital, capital expenditures, legal cash payments, acquisitions, separation effects, and share repurchases. The company’s annual reports and proxy materials provide the clearest source trail for those drivers.

What should a DCF model focus on?

The most important forecast variables are not all on the income statement. Revenue growth should be split between distribution volume, specialty product mix, branded-to-generic conversion, branded price changes, acquisitions, and technology-services demand where management discloses drivers. Margin assumptions should recognize that North American Pharmaceutical can add enormous revenue without lifting consolidated margin much, while Prescription Technology Solutions and Oncology & Multispecialty can change profit mix more materially. Free cash flow should reflect capital expenditures, capitalized software, working-capital swings, opioid-related cash payments, and acquisition spending.